ArticleJournal of clinical virology : the official publication of the Pan American Society for Clinical Virology2019
BioRad BioPlex® HIV Ag-Ab assay: Incidence of false positivity in a low-prevalence population and its effects on the current HIV testing algorithm.
Article in Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 14 citations in OpenAlex.
- Different approaches to HIV confirmation: a survey of three Italian regions.Frontiers in cellular and infection microbiology · 2026Article
- Anti-HIV Serological Profiles and Concordance of Chemiluminescent Immunoassay Screening With a Supplemental Rapid Test Among Blood Donors in Côte d'Ivoire.Journal of immunology research · 2026Article
- HIV testing algorithm using fourth generation reagents reduces the false positive rate of screening tests.Scientific reports · 2025Article
- DETECTION OF NEW HIV CASES UNDER EPIDEMIC CONTROL - WHEN IS IT THE RIGHT TIME TO REVIEW HIV TESTING ALGORITHMS FOR COUNTRIES NEARING THE 95-95-95 MILESTONES? CASE STUDY -BOTSWANA.African journal of infectious diseases · 2025Article
- Article
- Clinical Application Evaluation of ElecsysFrontiers in cellular and infection microbiology · 2022Article
- Data on the Relationships of Signal-To-Cutoff Ratios of Elecsys HIV Antigen/Antibody and Elecsys Syphilis Assays to Subsequent Confirmatory Testing at an Academic Medical Center.Data in brief · 2021Article
- A method to alleviate false-positive results of the Elecsys HIV combi PT assay.Scientific reports · 2021Article
- The evaluation of low cut-off index values of ElecsysJournal of clinical laboratory analysis · 2020Article
- Data on the relationship of signal-to-cutoff ratio of two HIV antigen/antibody combination assays to subsequent confirmation of HIV-1 infection in a low-prevalence population.Data in brief · 2020Article
- Could HIV-1 RNA Testing be an Option as the Second Step in the HIV Diagnostic Algorithm?Sexually transmitted diseases · 2020Article
- Decreased Seroreactivity in Individuals Initiating Antiretroviral Therapy during Acute HIV Infection.Journal of clinical microbiology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
backgroundThe BioPlex® HIV Ag-Ab assay, unlike other HIV 1/2 antigen/antibody immunoassays, is capable of differentiating positive HIV-1 antibodies (Groups M and O) from HIV-2 antibodies and/or HIV-1 p24 antigen in a single test.
objectiveThe Alaska State Virology Laboratory (ASVL) adopted the BioPlex® HIV Ag-Ab assay early 2017 and can report on its performance in terms of false positivity in a low-prevalence population and its effects on the current HIV testing algorithm recommended by the Centers for Disease Control and Prevention (CDC). STUDY
designSpecimens received between March 2017 and August 2018 were screened using the BioPlex® HIV Ag-Ab assay. Specimens screening positive for HIV antibodies or antigen were further confirmed using the Geenius™ HIV 1/2 Supplemental Assay and/or HIV RNA testing.
resultsOf the 12,338 sera screened by the BioPlex assay for HIV, 35 specimens were positive. Only 22 of the specimens were confirmed by supplemental testing and were considered to be truly positive (PPV, 62.9%). RNA was not detected in these cases suggesting initial false positivity on the BioPlex® HIV Ag-Ab assay. True positive results had index values (IDX) of >180 whereas false positive IDX's were between 1 and 4, with the exception of one specimen.
conclusionsWe suggest that specimens demonstrating positivity with low IDX values <4 on the BioPlex® HIV Ag-Ab assay proceed directly to RNA testing, essentially bypassing supplemental antibody confirmation tests, to reduce turnaround time and cost of HIV confirmation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.